29例肺粘液表皮样癌的临床分析
发布时间：2018-12-07 09:23
【摘要】：背景与目的肺粘液表皮样癌(mucoepidermoid carcinoma,MEC)是罕见的肺部恶性肿瘤,其临床特征及预后尚不完全明确,本研究旨在探讨肺粘液表皮样癌的临床特征、诊治方法及预后影响因素。方法回顾郑州大学附属肿瘤医院2006年1月-2015年12月收治的29例肺MEC患者的临床资料,对临床特征、诊断方法、治疗措施及预后进行分析。结果全组29例患者占同期新诊断肺癌的0.16%(29/18,021),其中男性18例,女性11例;中位年龄45岁(10岁-79岁);高级别肺MEC 17例,低级别12例。6例患者行表皮生长因子受体(epidermal growth factor receptor,EGFR)基因检测均未检测到突变。行手术为主的综合治疗17例,非手术治疗12例。中位随访时间35(5-114)个月,至随访结束,17例患者已死亡。全组1年、3年、5年生存率分别为65.5%、51.2%和39.4%,中位生存时间37个月。结论肺MEC发病率低,临床表现缺乏特异性,确诊主要依据术后组织病理,并辅以免疫组化标记结果,手术是主要的治疗方法,病理级别以高级别为主,其预后与组织学分级、临床分期密切相关,EGFR酪氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitor,EGFR-TKI)有望改善肺MEC的预后。
[Abstract]:Background & objective Pulmonary mucoepidermoid carcinoma (mucoepidermoid carcinoma,MEC) is a rare malignant tumor of the lung. Its clinical features and prognosis are not completely clear. This study aims to explore the clinical features, diagnosis and treatment methods and prognostic factors of pulmonary mucoepidermoid carcinoma. Methods the clinical data of 29 patients with pulmonary MEC admitted from January 2006 to December 2015 in affiliated Cancer Hospital of Zhengzhou University were reviewed. The clinical features, diagnostic methods, treatment measures and prognosis were analyzed. Results 29 patients accounted for 0.16% (29 / 18021) of newly diagnosed lung cancer in the same period, including 18 males and 11 females, with a median age of 45 years (10-79 years). There were 17 cases of high grade MEC and 12 cases of low grade. No mutation was detected in the epidermal growth factor receptor (epidermal growth factor receptor,EGFR) gene in 6 cases. 17 cases were treated with combined operation and 12 cases with non-operative treatment. The median follow-up time was 35 (5-114) months. By the end of follow-up, 17 patients had died. The 1-year, 3-year and 5-year survival rates were 65.5% and 39.4%, respectively. The median survival time was 37 months. Conclusion Pulmonary MEC has a low incidence and lack of specificity in clinical manifestations. The diagnosis is mainly based on postoperative histopathology and immunohistochemical results. Surgery is the main treatment method, and the pathological grade is mainly high grade, its prognosis and histological grading. EGFR tyrosine kinase inhibitor (EGFR-tyrosine kinase inhibitor,EGFR-TKI) may improve the prognosis of pulmonary MEC.
【作者单位】： 郑州大学附属肿瘤医院呼吸内科;
【分类号】：R734.2
本文编号：2366977
[Abstract]:Background & objective Pulmonary mucoepidermoid carcinoma (mucoepidermoid carcinoma,MEC) is a rare malignant tumor of the lung. Its clinical features and prognosis are not completely clear. This study aims to explore the clinical features, diagnosis and treatment methods and prognostic factors of pulmonary mucoepidermoid carcinoma. Methods the clinical data of 29 patients with pulmonary MEC admitted from January 2006 to December 2015 in affiliated Cancer Hospital of Zhengzhou University were reviewed. The clinical features, diagnostic methods, treatment measures and prognosis were analyzed. Results 29 patients accounted for 0.16% (29 / 18021) of newly diagnosed lung cancer in the same period, including 18 males and 11 females, with a median age of 45 years (10-79 years). There were 17 cases of high grade MEC and 12 cases of low grade. No mutation was detected in the epidermal growth factor receptor (epidermal growth factor receptor,EGFR) gene in 6 cases. 17 cases were treated with combined operation and 12 cases with non-operative treatment. The median follow-up time was 35 (5-114) months. By the end of follow-up, 17 patients had died. The 1-year, 3-year and 5-year survival rates were 65.5% and 39.4%, respectively. The median survival time was 37 months. Conclusion Pulmonary MEC has a low incidence and lack of specificity in clinical manifestations. The diagnosis is mainly based on postoperative histopathology and immunohistochemical results. Surgery is the main treatment method, and the pathological grade is mainly high grade, its prognosis and histological grading. EGFR tyrosine kinase inhibitor (EGFR-tyrosine kinase inhibitor,EGFR-TKI) may improve the prognosis of pulmonary MEC.
【作者单位】： 郑州大学附属肿瘤医院呼吸内科;
【分类号】：R734.2
【相似文献】
相关期刊论文 前10条
1 于长海;尹静;刘颖;李捷;;肺粘液表皮样癌的外科治疗与预后分析[J];临床肺科杂志;2010年03期
2 宗阳如;;肺粘液表皮样癌3例报告[J];武汉医学杂志;1993年03期
3 丁洪基，李新功，，房泽三;肺粘液表皮样癌1例[J];肿瘤;1995年01期
4 张继红,李瑞英;肺粘液表皮样癌1例[J];中国肿瘤临床;1999年04期
5 王梦歌;欧阳松云;孙培宗;陈壬寅;;低度恶性肺粘液表皮样癌并转移一例报告并文献复习[J];中国呼吸与危重监护杂志;2014年04期
6 潘璜,宛四海,傅森林;肺粘液表皮样癌2例分析[J];医学影像学杂志;2005年03期
7 何远智;白林;;青少年肺粘液表皮样癌一例报告[J];四川医学;1987年04期
8 何远智;白林;;青少年肺粘液表皮样癌一例报告[J];医学科技;1987年01期
9 李文梅,宋恕平,周登光;儿童肺粘液表皮样癌一例[J];实用癌症杂志;1993年01期
10 张玉玲;肺粘液表皮样癌一例[J];解放军医学情报;1994年02期
相关硕士学位论文 前2条
1 霍真;肺涎腺型癌的组织病理及分子病理研究[D];北京协和医学院;2015年
2 张洪岩;10例肺粘液表皮样癌病例临床资料分析[D];中国医科大学;2010年
本文编号：2366977
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2366977.html
